{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-foot/prescribing-information/oral-terbinafine/","result":{"pageContext":{"chapter":{"id":"476702d7-9e1a-5dfd-b3b0-899ebce5130b","slug":"oral-terbinafine","fullItemName":"Oral terbinafine","depth":2,"htmlHeader":"<!-- begin field e90d2dea-fee8-45e4-8b83-af3c46e6cf37 --><h2>Oral terbinafine</h2><!-- end field e90d2dea-fee8-45e4-8b83-af3c46e6cf37 -->","summary":"","htmlStringContent":"<!-- begin item ca922434-8b14-42c1-9bb1-65579269b7b2 --><!-- end item ca922434-8b14-42c1-9bb1-65579269b7b2 -->","topic":{"id":"32650c82-f347-5933-adc6-d0da00f3d764","topicId":"35b0fa0c-8988-453f-af54-60cd595d29ad","topicName":"Fungal skin infection - foot","slug":"fungal-skin-infection-foot","lastRevised":"Last revised in April 2018","chapters":[{"id":"66fe4516-176d-5ffc-aebd-99a58afbd57c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5231c18b-820c-586e-87f0-5527574f70d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e2b3169b-582d-5dda-b94f-73ccd139eede","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e1fd155-8f48-5bf7-a40c-4d2931a41736","slug":"changes","fullItemName":"Changes"},{"id":"8249fd1f-7c27-535b-a721-9e280d761ea5","slug":"update","fullItemName":"Update"}]},{"id":"e4ea5f16-99ef-5247-87e9-141b06d8b21a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"524d92eb-2792-5543-a6d9-78e4f825cf22","slug":"goals","fullItemName":"Goals"},{"id":"a678e6e3-5a4b-55cb-b7d6-c6ab9580eda2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"44708a93-b41d-5827-9293-650b191df0b0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d578224-3b80-58f6-9894-5c90e41c1b44","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a029f7b6-3344-51e6-ab22-bafdf196a4b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b487a461-1526-54bb-a2df-4e2e0562293d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0e034d35-5e8d-5db3-a518-77103caa73c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"73e18fb0-6f03-51ed-bddf-355959375e75","slug":"definition","fullItemName":"Definition"},{"id":"a33dea25-362f-5128-9c14-d178ef837bfe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"a4167228-e44b-560b-8406-20294a5b8e42","slug":"prevalence","fullItemName":"Prevalence"},{"id":"91f3fb6f-6926-547c-830c-dd963749fb55","slug":"complications","fullItemName":"Complications"},{"id":"8373f46b-763e-53e3-9ea8-90cd767d66e6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"090da929-a640-586e-a803-a47b38656e1d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"024c307f-3650-539d-b0b4-4f1c4a8db49e","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e3544fc8-cba9-524d-aed2-f28ae6f802e8","slug":"assessment","fullItemName":"Assessment"},{"id":"3ad14837-2b4c-58ab-b5c5-456d63d403ae","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"db051fa9-f61e-5787-bd5d-b2ff4a77ba85","fullItemName":"Management","slug":"management","subChapters":[{"id":"a11a4a32-6cc1-5c40-8396-099a218e1487","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"27a2a883-b20f-5b25-825b-3bc5b02c1f77","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"476702d7-9e1a-5dfd-b3b0-899ebce5130b","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"e3c1f25f-1a76-53af-aef4-b39eecdf04d7","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"4f73cab3-f311-54bd-beac-8bb860f26e2f","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"aaec6565-5327-5bd4-bc06-a1442065c1bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c64c0494-1e71-5960-a8c9-a05141d2801c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"265ba112-5e5e-59c8-8569-29d1a263263d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e7088451-abf0-5e2f-a546-109de8062cbf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"96559e5f-dca9-5c90-af8c-c1182e5d3306","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd075cd9-9444-5680-bd23-a168ebe2b5a2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"49b473c6-a745-5480-9602-1224549611f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"65b0f432-1967-593c-a9f7-2326776f4e83","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"743c10d9-bb6f-5776-9062-151848c13830","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 065817da-9dfb-47e5-a779-a8d200d72182 --><h3>Dosing schedule</h3><!-- end field 065817da-9dfb-47e5-a779-a8d200d72182 -->","summary":"","htmlStringContent":"<!-- begin item 133b975f-84d3-4437-9fe8-a8d200d71fa9 --><!-- begin field 0648568b-d31a-4b84-9b95-a8d200d72182 --><ul><li>For adults, prescribe terbinafine 250 mg once daily for 2–6 weeks, depending on the severity of infection.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 0648568b-d31a-4b84-9b95-a8d200d72182 --><!-- end item 133b975f-84d3-4437-9fe8-a8d200d71fa9 -->","subChapters":[]},{"id":"41951de4-39ec-5176-b32e-800bada8d9e6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 298bd926-2109-4a70-a0de-c01d509b0ad3 --><h3>Contraindications and cautions</h3><!-- end field 298bd926-2109-4a70-a0de-c01d509b0ad3 -->","summary":"","htmlStringContent":"<!-- begin item 691d6005-ff77-4af4-9abc-f6a9a2b46462 --><!-- begin field 35742354-976e-464f-ad3a-35cebdce46d6 --><p><strong>Do not prescribe terbinafine to people with:</strong></p><ul><li>Hepatic impairment — the manufacturer recommends that terbinafine should not be prescribed in people with chronic or active hepatic disease. It recommends for other people, liver function tests (LFTs) should be performed. Hepatotoxicity may occur in people with and without pre-existing hepatic disease, therefore periodic monitoring of LFTs (after 4–6 weeks of treatment) is recommended. Terbinafine should be stopped immediately if LFTs are deranged.</li><li>Severe renal impairment.</li></ul><p><strong>Prescribe terbinafine with caution to people with:</strong></p><ul><li>Autoimmune disease — risk of lupus erythematosus-like effect.</li><li>Psoriasis — increased risk of exacerbation of psoriasis.</li><li>Renal impairment — the BNF recommends that half the normal dose of terbinafine should be used if estimated glomerular filtration rate (eGFR) is less than 50 mL/min/1.73 m<sup>2</sup> and there is no suitable alternative. However, the manufacturer does not recommend using terbinafine in these people, as it has not been adequately studied.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 35742354-976e-464f-ad3a-35cebdce46d6 --><!-- end item 691d6005-ff77-4af4-9abc-f6a9a2b46462 -->","subChapters":[]},{"id":"d7157e1f-315f-5ffa-996c-2c8529004d99","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4eb2a235-6c74-467a-81ec-3827b2e7b6bb --><h3>Adverse effects</h3><!-- end field 4eb2a235-6c74-467a-81ec-3827b2e7b6bb -->","summary":"","htmlStringContent":"<!-- begin item d848a091-f45c-4f2b-9688-11394a8bf323 --><!-- begin field 923ffa29-9d97-466d-9a02-531a5264a08f --><p><strong>Adverse effects of terbinafine include:</strong></p><ul><li>Gastrointestinal — abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea, feeling of fullness (very common); pancreatitis (unknown frequency).</li><li>Nervous system — headache (common); taste disturbance (uncommon). Dizziness, paraesthesia, and hypoaesthesia (rare).</li><li>Skin and subcutaneous tissue — rash, urticarial (very common). Very rarely Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, skin eruption, dermatitis exfoliative, dermatitis bullous, photosensitivity reaction, and alopecia.</li><li>Other<ul><li>Anaphylaxis.</li><li>Arthralgia, myalgia, decreased appetite.</li><li>Hepatic dysfunction, jaundice, hepatitis, cholestasis — people taking terbinafine tablets should be warned to report immediately any signs and symptoms of unexplained persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale faeces. If these symptoms develop, terbinafine treatment should be stopped, and liver function tests (LFTs) should be immediately performed.</li><li>Malaise, neutropenia, agranulocytosis, thrombocytopenia, vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 923ffa29-9d97-466d-9a02-531a5264a08f --><!-- end item d848a091-f45c-4f2b-9688-11394a8bf323 -->","subChapters":[]},{"id":"7e0f8e03-dcab-51f6-82c3-9ede208992a6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b8886700-d8a3-4ee2-8e77-74d041345aab --><h3>Drug interactions</h3><!-- end field b8886700-d8a3-4ee2-8e77-74d041345aab -->","summary":"","htmlStringContent":"<!-- begin item 5d1a86e6-93cd-4129-9cdf-6fd332ddfad8 --><!-- begin field d046fab3-8bb0-42da-af53-c30077eb6e1d --><p><strong>Possible drug interactions with terbinafine include:</strong></p><ul><li>Codeine —<strong> </strong>the analgesic effect may be reduced or abolished by terbinafine. Monitor for analgesic efficacy.</li><li>Rifampicin — levels of terbinafine are reduced. Dose increases of terbinafine may be necessary.</li><li>Tamoxifen — avoid concurrent use. Metabolism to an active metabolite of tamoxifen may be inhibited by terbinafine. </li><li>Terbinafine levels may be increased by the following drugs if taken concomitantly:<ul><li>Amiodarone.</li><li>Fluconazole, ketoconazole.</li></ul></li><li>Terbinafine may increase levels of the following drugs if taken concomitantly, thereby increasing or prolonging their effects, including adverse effects:<ul><li>Anti-arrhythmics (flecainide, mexiletine, and propafenone).</li><li>Aripiprazole, risperidone.</li><li>Beta-blockers (carvedilol, metoprolol, nebivolol, propranolol, and timolol).</li><li>Dextromethorphan.</li><li>Monoamine oxidase inhibitors Type B (MAOIs-B, such as selegiline).</li><li>Selective serotonin reuptake inhibitors (sertraline, paroxetine).</li><li>Tramadol — terbinafine may increase levels of tramadol, but not the active metabolite, which causes an increase in adverse effects, but not in analgesic effect.</li><li>Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field d046fab3-8bb0-42da-af53-c30077eb6e1d --><!-- end item 5d1a86e6-93cd-4129-9cdf-6fd332ddfad8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}